Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details)

v3.25.0.1
Subsequent Events (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Jan. 28, 2025
Jan. 10, 2025
Jan. 01, 2025
Dec. 31, 2024
Jan. 31, 2025
Dec. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Subsequent Event [Line Items]                
Proceeds from the exercise of stock options             $ 18,000 $ 0
Employee Stock Option                
Subsequent Event [Line Items]                
Shares exercised           18,200    
Weighted-average exercise price           $ 1.72    
Proceeds from the exercise of stock options           $ 18,060,000    
2023 Omnibus Equity Incentive Plan | Employee Stock Option                
Subsequent Event [Line Items]                
Shares reserved for future issuance       120,950   120,950 120,950  
AstralBio Exclusive License Agreement                
Subsequent Event [Line Items]                
Payment of upfront licensing fee       $ 750,000        
Subsequent Events | Pre-Funded Warrants                
Subsequent Event [Line Items]                
Warrants, shares exercised         128,070      
Proceeds from exercise of warrants         $ 13      
Subsequent Events | Employee Stock Option                
Subsequent Event [Line Items]                
Shares exercised         48,300      
Weighted-average exercise price         $ 1.72      
Proceeds from the exercise of stock options         $ 83,076      
Subsequent Events | 2023 Omnibus Equity Incentive Plan | Employee Stock Option                
Subsequent Event [Line Items]                
Limit increase in shares available for future grant     458,383          
Shares reserved for future issuance     1,658,383          
Subsequent Events | At Market Issuance Sales Agreement | Placement Agents | At-The-Market Offerings | Common Stock                
Subsequent Event [Line Items]                
Common stock, shares issued         32,167      
Net proceeds from sale of equity         $ 102,000      
Subsequent Events | 2025 Purchase Agreement | Investors | Private placement | Common Stock                
Subsequent Event [Line Items]                
Common stock, shares issued   240,807            
Share price on new issues   $ 2.72            
Aggregate gross proceeds   $ 655,000            
Subsequent Events | AstralBio Exclusive License Agreement                
Subsequent Event [Line Items]                
Common stock, shares issued 246,087              
Payment of upfront licensing fee $ 750,000              
Number of shares issued as payment for upfront fee 246,087